---
title: "Why CRISPR Therapeutics stock has been on a roller-coaster ride this year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290212873.md"
description: "The opportunity is enormous, but uncertainty remains."
datetime: "2026-06-18T14:13:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290212873.md)
  - [en](https://longbridge.com/en/news/290212873.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290212873.md)
generator: "portal-rs"
---

# Why CRISPR Therapeutics stock has been on a roller-coaster ride this year

The opportunity is enormous, but uncertainty remains.

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)

## Related News & Research

- [CRISPR Therapeutics (NASDAQ:CRSP) Earns Market Outperform Rating from Citizens Jmp](https://longbridge.com/en/news/296922645.md)
- [Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP](https://longbridge.com/en/news/295199690.md)
- [13:27 ETPatients Representing the Power of Advanced Therapies to Take Center Stage at Emily Whitehead Foundation's 2026 Believe Ball](https://longbridge.com/en/news/297074492.md)
- [Silexion Therapeutics announces extraordinary shareholder meeting](https://longbridge.com/en/news/296915822.md)
- [Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts](https://longbridge.com/en/news/290700939.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**